Quinn Opportunity Partners LLC Sells 1,000 Shares of Halozyme Therapeutics, Inc. $HALO

Quinn Opportunity Partners LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,000 shares of the biopharmaceutical company’s stock after selling 1,000 shares during the quarter. Quinn Opportunity Partners LLC’s holdings in Halozyme Therapeutics were worth $312,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Jupiter Asset Management Ltd. raised its stake in Halozyme Therapeutics by 1,012.8% during the second quarter. Jupiter Asset Management Ltd. now owns 670,612 shares of the biopharmaceutical company’s stock worth $34,885,000 after acquiring an additional 610,350 shares in the last quarter. Boston Partners increased its position in Halozyme Therapeutics by 3.6% during the 2nd quarter. Boston Partners now owns 431,345 shares of the biopharmaceutical company’s stock worth $23,062,000 after purchasing an additional 15,020 shares in the last quarter. Allworth Financial LP increased its position in Halozyme Therapeutics by 607.1% during the 2nd quarter. Allworth Financial LP now owns 9,405 shares of the biopharmaceutical company’s stock worth $489,000 after purchasing an additional 8,075 shares in the last quarter. Profund Advisors LLC boosted its position in Halozyme Therapeutics by 40.2% in the second quarter. Profund Advisors LLC now owns 38,440 shares of the biopharmaceutical company’s stock valued at $2,000,000 after buying an additional 11,021 shares in the last quarter. Finally, Future Fund LLC grew its stake in shares of Halozyme Therapeutics by 64.7% during the second quarter. Future Fund LLC now owns 55,692 shares of the biopharmaceutical company’s stock worth $2,897,000 after buying an additional 21,873 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Bernadette Connaughton sold 4,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director owned 46,952 shares in the company, valued at $3,459,423.36. The trade was a 7.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company’s stock, valued at $50,721,994.47. The trade was a 2.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 110,227 shares of company stock worth $8,028,955. Corporate insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

HALO has been the subject of a number of research reports. Citizens Jmp increased their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 4th. Benchmark increased their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Morgan Stanley cut their price target on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Finally, JMP Securities lifted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 6th. Seven equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $75.00.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $70.63 on Thursday. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The firm’s fifty day simple moving average is $70.41 and its two-hundred day simple moving average is $63.07. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $79.50. The stock has a market capitalization of $8.31 billion, a P/E ratio of 16.16, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. During the same period in the previous year, the business earned $1.27 EPS. The firm’s revenue was up 22.1% compared to the same quarter last year. As a group, analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.